Arch Biopartners Inc.

Equities

ACHFF

CA03938C1041

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 03:57:08 2024-04-24 pm EDT			5-day change	1st Jan Change
1.55 ^USD	-4.32%		-9.88%	+38.83%

Apr. 16	Arch Biopartners Says St. Michael's Hospital Joins Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-AKI	MT
Apr. 16	Arch Biopartners Brief: Says St. Michael's Hospital Joins Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury	MT

Arch Biopartners Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2022

August 28, 2022

Arch Biopartners Inc. reported earnings results for the third quarter and nine months ended June 30, 2022. For the third quarter, the company reported net loss was CAD 0.247394 million compared to net income of CAD 0.881969 million a year ago. Basic loss per share from continuing operations was CAD 0.004 compared to basic earnings per share from continuing operations of CAD 0.014 a year ago.
For the nine months, net loss was CAD 0.909852 million compared to CAD 1.82 million a year ago. Basic loss per share from continuing operations was CAD 0.015 compared to CAD 0.03 a year ago.

Latest news about Arch Biopartners Inc.

Arch Biopartners Says St. Michael's Hospital Joins Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-AKI	Apr. 16	MT
Arch Biopartners Brief: Says St. Michael's Hospital Joins Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury	Apr. 16	MT
Arch Biopartners Inc. Announces St. Michael's Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury	Apr. 16	CI
Arch Biopartners Says University Health Network Joining Phase II Trial of LSALT Peptide	Apr. 03	MT
Anesthesia Clinical Trials Unit Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery-Associated-Acute Kidney Injury	Apr. 03	CI
Arch Biopartners Adds Three Clinical Sites in Turkey For Phase II Trial for LSALT Peptide	Apr. 02	MT
Arch Biopartners Adds Three New Clinical Sites into the Phase Ii Trial for Lsalt Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury	Apr. 02	CI
Arch Biopartners Clinical Team Publishes Data from Phase II Trial for LSALT Peptide Targeting Organ Inflammation	Mar. 18	MT
Arch Biopartners Clinical Team Publishes Data from Phase II Trial for Lsalt Peptide Targeting Organ Inflammation in Hospitalized Patients Infected with Sars-Cov-2	Mar. 18	CI
Arch Biopartners Says University of Calgary Joins Phase II Trial of LSALT Peptide Targeting Cardiac Surgery-Associated AKI	Mar. 15	MT
University of Calgary Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury	Mar. 15	CI
Arch Biopartners Announces Dosing Of Patient In Phase II Trial For LSALT Peptide	Mar. 07	MT
Arch Biopartners Inc. Announces Dosing of First Patient in Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated-Acute Kidney Injury	Mar. 07	CI
Arch Biopartners Receives Health Canada Approval to Conduct Phase II Trial for Lsalt Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury	Feb. 29	CI
Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase Ii Cardiac Surgery Associated-Acute Kidney Injury Trial for Lsalt Peptide	Feb. 29	CI
Arch Biopartners Receives Permission from U.S. FDA to Proceed with Phase II Acute Kidney Injury Trial	Feb. 29	CI
Arch Biopartners Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	Feb. 28	CI
Arch Biopartners on Pre-IND Meeting With FDA to Repurpose Cilastatin as New Treatment to Prevent Acute Kidney Injury	Feb. 27	MT
Arch Biopartners Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	Jan. 28	CI
Arch Biopartners Inc.(TSXV:ARCH) added to S&P/TSX Venture Composite Index	Jan. 22	CI
Arch Biopartners Receives Health Canada Approval to Conduct Phase II Trial For LSALT Peptide	Jan. 10	MT
Arch Biopartners Inc. Receives Health Canada Approval to Conduct Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury	Jan. 10	CI
Arch Biopartners Receives Approval from Turkish Ministry of Health to Proceed with Phase II Trial for LSALT Peptide	Jan. 03	MT
Arch Biopartners Inc. Receives Approval from the Ministry of Health to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury	Jan. 03	CI
Arch Biopartners Inc. Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide	Dec. 21	CI

Chart Arch Biopartners Inc.

Duration

Period

More charts

Company Profile

Arch Biopartners Inc. is a portfolio-based biotechnology company focused on the development of technologies that have the potential to make a medical or commercial impact. The Company is focused on the clinical development of its drug platform in targeting dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver and kidneys. Its lead drug candidate is LSALT Peptide (Metablok). LSALT Peptide is developed for targeting organ inflammation often experienced in hospitalized COVID-19 patients. It focuses on therapeutic development of LSALT Peptide and other DPEP-1 targeting drug candidates for new indications where inflammation of the lungs, liver and kidneys is an unmet problem. It has additional technology platforms in its portfolio including AB569, which focuses on preventing antibiotic resistant bacterial infections; Borg, which is a peptide-solid surface interface, and MetaMx, which is a synthetic molecule that target brain tumor initiating cells and invasive glioma cells.

Sector

Biotechnology & Medical Research

Calendar

2024-05-27 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

2.127 CAD

Average target price

3.5 CAD

Spread / Average Target

+64.56%

Consensus

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ARCH BIOPARTNERS INC.	+38.83%	97.43M
IQVIA HOLDINGS INC.	+4.09%	43.84B
LONZA GROUP AG	+46.73%	41.25B
MODERNA, INC.	+9.45%	41.68B
CELLTRION, INC.	-10.92%	27.04B
ICON PUBLIC LIMITED COMPANY	+9.32%	25.53B
ALNYLAM PHARMACEUTICALS, INC.	-24.87%	18.18B
MEDPACE HOLDINGS, INC.	+29.70%	12.29B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.28%	12.29B
UNITED THERAPEUTICS CORPORATION	+7.78%	11.15B

Other Biotechnology & Medical Research